Novo Nordisk A/S (NVO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $183.52B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novo Nordisk A/S (NVO) Financials: Revenue, Profit and Cash Flow
Novo Nordisk A/S reported revenue of DKK 309.06B for the fiscal year ended Dec 31, 2025, up 6.4% from the year before. That year, net income was DKK 102.43B with a net margin of 33.1%, operating cash flow was DKK 119.10B and free cash flow was DKK 28.99B. The quarter ended Sep 30, 2026 had revenue of DKK 79.19B and net income of DKK 16.74B.
Revenue and Margins
The operating margin was 41.3% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from DKK 111.78B, a compound annual rate of 12.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 309.06B | +6.4% | 81.0% | 41.3% | 33.1% |
| Dec 2024 | 290.40B | +25.0% | 84.7% | 44.2% | 34.8% |
| Dec 2023 | 232.26B | +31.3% | 84.6% | 44.2% | 36.0% |
| Dec 2022 | 176.95B | +25.7% | 83.9% | 42.3% | 31.4% |
| Dec 2021 | 140.80B | +10.9% | 83.2% | 41.7% | 33.9% |
| Dec 2020 | 126.95B | +4.0% | 83.5% | 42.6% | 33.2% |
| Dec 2019 | 122.02B | +9.1% | 83.5% | 43.0% | 31.9% |
| Dec 2018 | 111.83B | +0.1% | 84.2% | 42.2% | 34.5% |
| Dec 2017 | 111.70B | -0.1% | 84.2% | 43.8% | 34.1% |
| Dec 2016 | 111.78B | N/A | 84.6% | 43.3% | 33.9% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1.4% from the year before. In the quarter ended Sep 2026, net income fell 16.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 309.06B | 290.40B | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B |
| Cost of revenue | 58.79B | 44.52B | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B |
| Gross profit | 250.28B | 245.88B | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B |
| Research and development | 52.04B | 48.06B | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.80B | 14.01B | 14.56B |
| Operating income | 127.66B | 128.34B | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B |
| Net income | 102.43B | 100.99B | 83.68B | 55.52B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.92B |
| EBITDA | 156.73B | 147.94B | 114.63B | 76.80B | 65.39B | 59.27B | 54.43B | 51.63B | 51.95B | 51.06B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79.19B | 78.49B | 96.82B | 79.14B | 74.98B | 76.86B | 78.09B | 85.68B | 71.31B | 68.06B | 65.35B | 65.86B |
| Gross profit | 60.96B | 61.39B | 83.22B | 64.00B | 57.07B | 64.01B | 65.20B | 72.66B | 60.00B | 57.79B | 55.43B | 55.85B |
| Operating income | 23.01B | 27.06B | 59.62B | 31.74B | 23.68B | 33.45B | 38.79B | 36.74B | 33.82B | 25.93B | 31.85B | 26.77B |
| Net income | 16.74B | 20.99B | 48.56B | 26.89B | 20.01B | 26.50B | 29.03B | 28.23B | 27.30B | 20.05B | 25.41B | 21.96B |
Balance Sheet
As of Dec 2025, total debt of DKK 130.96B exceeded cash and equivalents by 104.49B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 542.90B | 465.80B | 314.49B | 241.26B | 194.51B | 144.92B | 125.61B | 110.77B | 102.36B | 97.54B |
| Current assets | 172.45B | 160.90B | 139.65B | 108.19B | 85.59B | 65.81B | 62.46B | 59.07B | 60.08B | 59.77B |
| Cash and equivalents | 26.46B | 15.65B | 14.39B | 12.65B | 10.72B | 12.76B | 15.47B | 15.64B | 18.85B | 18.69B |
| Total liabilities | 348.86B | 322.31B | 207.93B | 157.77B | 123.76B | 81.60B | 68.02B | 58.93B | 52.54B | 52.27B |
| Short-term debt | 12.02B | 13.11B | 6.48B | 1.47B | 13.68B | 7.46B | 1.47B | 515.00M | 1.69B | 229.00M |
| Long-term debt | 118.94B | 84.25B | 15.98B | 20.77B | 9.65B | N/A | 0 | 0 | 0 | 0 |
| Shareholder equity | 194.05B | 143.49B | 106.56B | 83.49B | 70.75B | 63.33B | 57.59B | 51.84B | 49.81B | 45.27B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 599.16B | 594.94B | 559.22B | 542.90B | 512.29B | 482.15B | 489.16B | 465.80B | 397.44B | 53.09B | 298.92B | 314.49B |
| Total liabilities | 381.36B | 373.66B | 356.16B | 348.86B | 342.39B | 314.09B | 350.62B | 322.31B | 276.92B | 36.91B | 200.01B | 207.93B |
| Cash and equivalents | 44.15B | 44.48B | 21.13B | 26.46B | 32.08B | 18.43B | 38.94B | 15.65B | 57.02B | 7.59B | 6.32B | 14.39B |
| Shareholder equity | 217.80B | 221.28B | 203.06B | 194.05B | 169.90B | 168.07B | 138.54B | 143.49B | 120.52B | 16.17B | 98.91B | 106.56B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 24.3% of operating cash flow. Dividends came to 178.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 119.10B | 120.97B | 108.91B | 78.89B | 55.00B | 51.95B | 46.78B | 44.62B | 41.17B | 48.31B |
| Capital expenditures | 90.11B | 51.31B | 38.90B | 14.75B | 7.38B | 22.08B | 11.23B | 12.41B | 8.65B | 8.27B |
| Free cash flow | 28.99B | 69.66B | 70.01B | 64.13B | 47.62B | 29.87B | 35.55B | 32.21B | 32.52B | 40.05B |
| Dividends paid | 51.76B | 44.14B | 31.77B | 25.30B | 21.52B | 20.12B | 19.41B | 19.05B | 18.84B | 23.83B |
| Investing cash flow | -79.16B | -128.90B | -43.89B | -24.92B | -31.61B | -22.44B | -11.51B | -12.08B | -6.57B | -6.79B |
| Financing cash flow | -28.41B | 8.73B | -63.16B | -51.80B | -25.49B | -32.24B | -35.48B | -34.52B | -35.69B | -38.89B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 41.24B | 55.20B | 24.08B | 7.62B | 46.11B | 40.78B | 24.59B | 12.30B | 43.85B | 50.50B | 14.31B | 9.55B |
| Capital expenditures | 13.15B | 12.80B | 12.04B | 43.84B | 15.41B | 16.27B | 14.59B | 16.56B | 12.50B | 13.24B | 9.01B | 16.44B |
| Free cash flow | 28.10B | 42.40B | 12.04B | -36.22B | 30.69B | 24.51B | 10.01B | -4.26B | 31.35B | 37.27B | 5.30B | -6.88B |
Frequently Asked Questions About NVO
What is Novo Nordisk A/S's annual revenue?
Novo Nordisk A/S reported revenue of DKK 309.06B for the fiscal year ended Dec 31, 2025.
How fast is Novo Nordisk A/S's revenue growing?
Revenue was up 6.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.4%.
Is Novo Nordisk A/S profitable?
Yes. Novo Nordisk A/S reported net income of DKK 102.43B for the fiscal year ended Dec 31, 2025, with a net margin of 33.1%.
How much free cash flow does NVO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of DKK 119.10B minus capital expenditures of DKK 90.11B produced free cash flow of DKK 28.99B.
How much debt does Novo Nordisk A/S have?
The balance sheet dated Dec 31, 2025 reported long-term debt of DKK 118.94B, short-term debt of DKK 12.02B and cash and equivalents of DKK 26.46B.
NVO pages: Overview, Dividends, Financials, Valuation, Competitors